Suven Life Sciences Ltd
NSE:SUVEN
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
77.25
164.66
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one SUVEN stock under the Base Case scenario is 2.1 INR. Compared to the current market price of 117.47 INR, Suven Life Sciences Ltd is Overvalued by 98%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Suven Life Sciences Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for SUVEN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Suven Life Sciences Ltd
Balance Sheet Decomposition
Suven Life Sciences Ltd
Current Assets | 1.9B |
Cash & Short-Term Investments | 1.7B |
Receivables | 63.9m |
Other Current Assets | 136.9m |
Non-Current Assets | 254m |
Long-Term Investments | 486k |
PP&E | 251.6m |
Intangibles | 1.8m |
Other Non-Current Assets | 59k |
Current Liabilities | 179.3m |
Accounts Payable | 46.1m |
Other Current Liabilities | 133.2m |
Non-Current Liabilities | 13.4m |
Other Non-Current Liabilities | 13.4m |
Earnings Waterfall
Suven Life Sciences Ltd
Revenue
|
84.1m
INR
|
Operating Expenses
|
-1.7B
INR
|
Operating Income
|
-1.7B
INR
|
Other Expenses
|
192.9m
INR
|
Net Income
|
-1.5B
INR
|
Free Cash Flow Analysis
Suven Life Sciences Ltd
INR | |
Free Cash Flow | INR |
The company acknowledged the current challenging environment, particularly in the agrochemical sector, attributing difficulties to transient destocking issues. Despite a soft current quarter, management expressed confidence in a robust recovery for the '24-'25 period, bolstered by strong protection for the CDMO business and an increasing number of client inquiries.
What is Earnings Call?
SUVEN Profitability Score
Profitability Due Diligence
Suven Life Sciences Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Suven Life Sciences Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
SUVEN Solvency Score
Solvency Due Diligence
Suven Life Sciences Ltd's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Score
Suven Life Sciences Ltd's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SUVEN Price Targets Summary
Suven Life Sciences Ltd
Dividends
Current shareholder yield for SUVEN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
SUVEN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Suven Life Sciences Ltd. engages on discovering, developing, and commercializing novel pharmaceutical products which are used in classic therapies. The company is headquartered in Hyderabad, Telangana and currently employs 117 full-time employees. The firm is focused on discovering and developing new chemical entities (NCEs), which are central nervous system therapies for the treatment of cognitive disorders, depressive disorders, sleep disorders, psychiatric disorders, pain and inflammation, gastrointestinal motility disorders. Its research targets include serotonin 6 receptor, serotonin 4 receptor, histamine 3 receptor, Nicotinic acetylcholine (Alpha4beta2) receptor, muscarinic M1 receptor, muscarinic M4 receptor, multimodal and P2X purinoceptor 7 receptor. The company provides a range of Drug Discovery and Development Support Services (DDDSS). The firm offers research services specializing in synthetic, medicinal and analytical chemistry, in-vitro assay development and screening, drug metabolism and pharmacokinetics, toxicology and safety pharmacology, bioanalysis, and NCE formulations.
Contact
IPO
Employees
Officers
The intrinsic value of one SUVEN stock under the Base Case scenario is 2.1 INR.
Compared to the current market price of 117.47 INR, Suven Life Sciences Ltd is Overvalued by 98%.